Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks

4. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders In Q3 2024: 106

Eli Lilly and Company (NYSE:LLY) is one of the hottest healthcare stocks on the market courtesy of its weight loss drugs. The show dedicated quite a bit of airtime to the firm as Cramer was covering the JPMorgan Healthcare Conference as it was being aired. He interviewed Eli Lilly and Company (NYSE:LLY)’s CEO David Ricks as part of the coverage, and commented on the stock before and after the interview. Here’s what Cramer said:

“Yeah, I think that you’re gonna see some numbers at [a] level of growth that that’s unheard of frankly for a new drug. Some numbers to be put out that I think are really what you would get at for ten years. Blockbuster, blockbuster, I mean $25 billion. Now initially people are going to sell the stock, they’re gonna sell the stock because somehow they believe that it’s gonna miss the fourth quarter. The fourth quarter was always etched in stone. It was going to not be as good as their numbers. So David, it’s very hard to have a surprise when we already knew what they were going to do and it was in line. I suggest that people listen to our interview with David Ricks and figure out what 2025’s going to be, because 2024, already in the history books, doesn’t matter to the stock.”

“[on guidance of 32% midpoint revenue growth for 2025] Yeah, 32% very good numbers, I think what we’re going to have to focus on David, we’re going to have to ask Mr. Ricks about inventory, how much was there to sell, the demand side is insane, I care about demand more than I care about what these numbers are indicating. Let them sell, I look at it almost as you would on a trading desk, let them sell it. Let the uninformed people sell it. And then look at the size of this market, realize that we’re in its infancy. And its infancy is already so much bigger than any drug I’ve ever seen. I think you have to be on the horse that is Eli Lilly.”

“I think the problem with Eli Lilly is, as David Ricks admitted, there’s been some mistakes. They have not done the launch as easily as people thought. I say as I said in the beginning, let em sell it. I mean in the end this is the, GLP-1s the greatest drug of all time. It will be used for multiple indications. People wanted David Ricks to come out here and say, you know what, next year’s going to be far bigger than expected. He doesn’t play that game. It has never been the way he does things. We sold some stock when it was in the eight hundred, nine hundred, for my charitable trust. All I can say is, now I’m restricted, I can’t buy it back right now. I wish I could, down eight percent. I think it goes down ten percent as we get rid of people who don’t understand the story. And then people come in who understand the story, and they’ll buy the stock.”